Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Globe Newswire7-06-2024, 15:30
B.C. First Nations Languages Report Shows Increase in 23-02-2023, 00:21